List of Excipients in Branded Drug DACARBAZINE

Generic Drugs Containing DACARBAZINE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	dacarbazine	0143-9245	ANHYDROUS CITRIC ACID
Hikma Pharmaceuticals USA Inc	dacarbazine	0143-9245	MANNITOL
Teva Parenteral Medicines Inc	dacarbazine	0703-5075	ANHYDROUS CITRIC ACID
Teva Parenteral Medicines Inc	dacarbazine	0703-5075	MANNITOL
Fresenius Kabi USA LLC	dacarbazine	63323-127	CITRIC ACID MONOHYDRATE
Fresenius Kabi USA LLC	dacarbazine	63323-127	MANNITOL
Meitheal Pharmaceuticals Inc	dacarbazine	71288-174	ANHYDROUS CITRIC ACID

What are the Most Frequently-Used Excipients in DACARBAZINE?

# Of NDCs	Excipient
3	ANHYDROUS CITRIC ACID
1	CITRIC ACID MONOHYDRATE
4	MANNITOL

Dacarbazine Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Dacarbazine is an old, generic sterile oncology injectable with limited formulation complexity but meaningful handling constraints. The principal commercial opportunity is not a new active ingredient or biosimilar pathway. It is a differentiated injectable platform built around light protection, reconstitution speed, in-use stability, reduced pharmacy labor, and reliable supply. The strongest product concepts are ready-to-use or ready-to-dilute presentations supported by validated stability data and hospital workflow advantages.

What is the current formulation and regulatory status of dacarbazine?

Dacarbazine is a small-molecule alkylating antineoplastic agent used primarily for metastatic malignant melanoma and as part of combination regimens for Hodgkin lymphoma. It is administered intravenously after reconstitution and dilution.

Attribute	Dacarbazine profile
Active ingredient	Dacarbazine, also known as DTIC
Dosage form	Sterile lyophilized powder for injection
Common strengths	100 mg and 200 mg vials
Route	Intravenous infusion
Therapeutic areas	Melanoma, Hodgkin lymphoma and other oncology protocols
FDA pathway	Abbreviated New Drug Application for most current generic products
Biologic status	Not applicable; dacarbazine is a small molecule
Primary technical constraints	Light sensitivity, aqueous instability and alkaline incompatibility
Main commercial buyers	Hospitals, oncology clinics, group purchasing organizations and distributors

The original U.S. product, DTIC-Dome, established the reference formulation. Current generic products generally use a sterile powder that is reconstituted with Sterile Water for Injection and then diluted in compatible intravenous fluids. Product-specific labels govern concentration, storage, post-reconstitution use period and container requirements (U.S. Food and Drug Administration [FDA], n.d.-a).

The formulation is intentionally simple. Many marketed products contain dacarbazine with limited or no conventional excipient load, although composition can differ by manufacturer and jurisdiction. Citric acid or another pH-adjusting component may be used in some presentations. The commercial strategy should therefore begin with a product-by-product assessment of inactive ingredients, not an assumption that all dacarbazine vials are compositionally identical.

What excipients are suitable for dacarbazine injection?

The most defensible excipient strategy is a low-excipient, acidic, lyophilized formulation that preserves chemical stability without creating new toxicity or compatibility concerns.

pH-control excipients

Dacarbazine products are typically formulated under acidic conditions. Citric acid is commercially relevant because it can provide pH control in a parenteral lyophilized product. Alternative buffering systems may be technically feasible, but stronger buffers can create compatibility or degradation risks.

The formulation target should avoid unnecessary buffer capacity. A lightly adjusted acidic system can reduce the risk that dilution into an inappropriate fluid will shift the product into an unstable pH range. Sodium phosphate and other alkaline or near-neutral systems require particular caution because dacarbazine is incompatible with alkaline solutions.

Bulking agents and lyophilization aids

Mannitol is a conventional parenteral bulking agent and may support cake structure, handling and reconstitution performance. It can be relevant when the formulation needs a robust lyophilized cake or when the active ingredient alone does not provide adequate mass for manufacturing.

Potential alternatives include sucrose or trehalose, but their value must be demonstrated through stability, residual-moisture, reconstitution and particulate testing. Sugars can alter cake morphology and may introduce additional analytical and regulatory work. For dacarbazine, a simple mannitol-based formulation may be commercially easier to justify than a more complex stabilizer system.

Tonicity agents

Tonicity adjustment is usually less important before reconstitution because the marketed product is a dry powder. If the product is developed as a ready-to-use or concentrated liquid, sodium chloride or another tonicity agent may be considered. The liquid route carries greater stability risk and may require oxygen control, light protection and a more aggressive container-closure package.

Surfactants

Polysorbates and other surfactants should not be added without a defined need. A surfactant may help in a liquid formulation, but it can create additional risks involving peroxide formation, particulate generation, leachables and long-term storage. A surfactant-free product is preferable if acceptable reconstitution and container compatibility can be achieved.

Preservatives

A multidose preserved vial is unlikely to be the best commercial direction. Dacarbazine is used in oncology settings where single-dose handling is standard, and preservative-free presentation reduces exposure to benzyl alcohol, phenol or other antimicrobial agents. Preservatives can also create pediatric, toxicity and compatibility concerns.

What formulation patents could protect a dacarbazine product?

A new patent estate would need to protect more than the basic use of dacarbazine. The compound and its principal oncology indications are old, so broad composition-of-matter or ordinary method-of-use claims are unlikely to create meaningful exclusivity.

Potential claim area	Commercial value	Patent strength
New salt or polymorph	Low to moderate	Dependent on demonstrable technical advantage
Lyophilized composition	Moderate	Stronger if it provides unexpected stability or reconstitution performance
Ready-to-use liquid	Moderate to high	Potentially valuable if long-term stability is substantially improved
Light-protective container system	Moderate	Best protected through integrated formulation and packaging claims
Premixed infusion bag	High operational value	Patentability depends on stability and container interaction data
Rapid reconstitution method	Moderate	More likely to support process or device claims
Manufacturing process	Moderate	Useful for trade-secret protection and potential patent claims
Dosing method	Low	Most conventional dosing concepts are likely crowded or old

The most promising patent strategy is a formulation-plus-container system. A claim directed only to "dacarbazine in an opaque vial" would face obviousness and prior-art challenges. A stronger filing would connect a defined excipient range, residual-moisture specification, oxygen or light transmission limit, reconstitution time, impurity profile and storage period.

A ready-to-use product could support claims covering dacarbazine concentration, pH range, infusion-compatible container material, light exposure limits and stability after removal from secondary packaging. The commercial value would depend on showing a material improvement over the current powder product.

When does dacarbazine lose exclusivity?

Dacarbazine lost its primary product exclusivity decades ago. It is a mature generic molecule, and ordinary patent expiration does not currently prevent generic competition.

Exclusivity category	Dacarbazine position
Original compound patent	Expired
Original FDA marketing exclusivity	Expired
Current reference-product exclusivity	None expected for the conventional product
New formulation exclusivity	Available only if a novel product receives qualifying approval
Orphan-drug exclusivity	Product- and indication-specific; not a general barrier to dacarbazine competition
Biosimilar exclusivity	Not applicable
Generic entry	Generally permitted subject to ANDA approval and supply capability

The relevant commercial protection for a new product would come from patents on a differentiated formulation, container, device or manufacturing process. Regulatory exclusivity could arise for a genuinely new indication or qualifying product, but an ordinary generic powder-for-injection product is unlikely to receive meaningful new exclusivity.

What is the Orange Book status of dacarbazine?

The FDA Orange Book is the controlling source for current reference-listed drug status, therapeutic-equivalence evaluations and listed patent information. Dacarbazine is generally positioned as a conventional injectable generic rather than a product protected by a current, commercially significant patent listing.

An applicant should review the active Orange Book entries for the applicable strength, dosage form and reference product before filing. A typical 505(j) strategy would focus on:

1. Confirming the reference-listed drug and dosage-form equivalence.
2. Reviewing all current patent and exclusivity listings.
3. Selecting Paragraph I, II, III or IV certification as applicable.
4. Establishing pharmaceutical equivalence and bioequivalence through the FDA’s injectable-product framework.
5. Demonstrating sterility, endotoxin control, particulate compliance and container-closure integrity.

A Paragraph IV challenge may be relevant only if an active listed patent covers a newer dacarbazine formulation or delivery system. For the conventional lyophilized injectable, the principal barriers are technical execution, manufacturing economics and supply reliability rather than Orange Book patent blocking.

Which companies are challenging dacarbazine patents?

No broad, high-value patent dispute is generally associated with the conventional dacarbazine injectable. Competition is more likely to occur through ANDA filings, procurement tenders, manufacturing transfers and supply contracts than through major Paragraph IV litigation.

Potential litigation exposure would increase if a sponsor introduced:

• A ready-to-use dacarbazine infusion;
• A proprietary premixed bag;
• A long-term stable liquid formulation;
• A novel lyophilization cycle with product-specific claims;
• A specialized light-protective administration system; or
• A new oncology indication with patentable clinical use limitations.

Settlement agreements are therefore unlikely to be the main market variable for the established powder product. Any settlement involving a new formulation would need review through court dockets, FDA patent listings and public company disclosures. Generic entrants should not assume that the absence of legacy litigation eliminates risk around newly patented presentations.

What manufacturing and IP barriers affect dacarbazine?

Dacarbazine is technically manageable but operationally sensitive. The key manufacturing barriers are stability control and sterile injectable execution.

Light protection

Dacarbazine is light sensitive. Manufacturing, inspection, labeling, packaging and pharmacy handling should limit exposure. Commercial options include amber glass, opaque secondary packaging, foil overwraps and administration instructions requiring light protection.

Packaging can be a meaningful product differentiator if it reduces pharmacy handling while maintaining label compliance. A package that provides light protection through the full preparation and administration workflow has greater value than a vial that is protected only during storage.

Moisture and residual-water control

Lyophilized products require controlled residual moisture. Excess moisture can affect degradation, cake structure and reconstitution. A sponsor should link the residual-moisture specification to real-time stability rather than selecting a generic target.

Container closure

Rubber stopper selection is important because acidic formulations and oncology products can interact with elastomers, coatings or extractables. The container-closure system should be evaluated for adsorption, leachables, particulate generation and oxygen transmission.

Sterile manufacturing

The product requires validated aseptic processing or terminal sterilization where technically feasible. Commercial facilities must manage low-volume oncology batches, potent-compound handling, cleaning validation and cross-contamination controls.

Supply-chain resilience

Dacarbazine has a limited-volume market. A manufacturer can gain share through dual API sourcing, regional fill-finish capacity, inventory buffers and reliable distributor service. The commercial premium for supply continuity may exceed the premium available from a marginal excipient change.

What commercial opportunities exist for dacarbazine excipient innovation?

The best opportunities are workflow-driven rather than molecule-driven.

Product concept	Customer benefit	Commercial attractiveness
Standard lyophilized vial with improved light packaging	Lower handling risk	Moderate
Faster-reconstituting powder	Reduced pharmacy labor	Moderate
Higher-strength vial	Fewer vial punctures and less waste	Moderate
Ready-to-dilute concentrate	Shorter preparation time	High if stability is proven
Ready-to-use infusion bag	Minimal compounding	High, with greater development risk
Small-volume presentation	Better fit for low-dose protocols	Moderate
Kit with diluent and light-protective components	Simplified preparation	Moderate
Regional contract-manufacturing platform	Improved availability	High for institutional buyers

A ready-to-use infusion is the highest-value formulation concept because it can reduce compounding steps, exposure risk and preparation time. Its main risks are liquid instability, adsorption, container interaction, microbial control and transportation under controlled light conditions.

A ready-to-dilute concentrate may provide a better balance between value and technical feasibility. It reduces pharmacy preparation without requiring the same shelf-life performance as a fully premixed infusion. A concentrated liquid must still address pH, precipitation, degradation and compatibility with common infusion fluids.

How does dacarbazine compare with competing oncology injectables?

Dacarbazine competes with newer therapies in melanoma and Hodgkin lymphoma, but its commercial role differs from that of immune checkpoint inhibitors and targeted agents.

Product class	Dacarbazine position
Immune checkpoint inhibitors	Lower-cost legacy alternative; often less clinically favored in modern melanoma
Targeted melanoma therapies	Used less frequently where actionable mutations and newer standards apply
ABVD-related agents for Hodgkin lymphoma	Disease-specific role; product selection depends on regimen and guideline
Other generic cytotoxics	Competes primarily on price, availability and hospital contracting
Oral oncology products	Injectable administration remains a differentiator and burden

Dacarbazine’s mature clinical profile limits pricing power. A differentiated formulation must therefore demonstrate measurable economic value, such as fewer preparation steps, lower drug waste, lower occupational exposure risk or improved shortage resilience.

What generic launch risks exist for a new dacarbazine product?

A conventional generic launch faces modest patent risk but substantial execution risk.

Key risks include:

• Small addressable market and limited annual volume;
• Price compression from multiple injectable suppliers;
• API sourcing concentration;
• Product shortages caused by manufacturing interruptions;
• Failed stability studies for liquid or premixed presentations;
• Reconstitution or particulate failures;
• Hospital preference for established suppliers;
• Low return on specialized packaging unless procurement recognizes the benefit;
• Regulatory delay from formulation differences relative to the reference product.

A sponsor should prioritize an abbreviated development path for the standard powder product and reserve more complex liquid or premixed concepts for a second-generation product. A dual-track strategy can establish market access while building proprietary formulation protection.

What licensing deals and partnership models are relevant?

Dacarbazine is suitable for targeted licensing rather than large platform transactions. Commercial partnership opportunities include:

• Licensing a stable ready-to-use formulation;
• Contract manufacturing with an established oncology injectable facility;
• Regional rights for hospital markets;
• Co-development of a premixed infusion bag;
• Supply agreements with group purchasing organizations;
• Packaging partnerships for light-protective administration systems;
• API and fill-finish dual-source arrangements.

The most valuable asset is likely to be a validated product with manufacturing scale and institutional adoption, not an early-stage excipient concept. A licensor should provide comparative stability, preparation-time data, container-closure results and hospital workflow evidence.

Key Takeaways

• Dacarbazine is a mature small-molecule injectable with no meaningful biosimilar issue and limited conventional patent barriers.
• The standard formulation is a sterile lyophilized powder requiring reconstitution and light protection.
• Citric acid, mannitol and other excipients may be useful, but a minimal-excipient strategy is generally preferable.
• The strongest formulation opportunity is a stable ready-to-dilute or ready-to-use liquid product.
• Patent value would come from a demonstrated formulation, packaging or manufacturing advantage, not from dacarbazine itself.
• Generic competition is driven mainly by price, supply reliability, pharmacy convenience and regulatory execution.
• The best commercial positioning is a hospital-workflow product with validated stability and reliable supply.

FAQs

Is dacarbazine an excipient-sensitive drug?

Yes. Its formulation is sensitive to pH, light exposure, moisture and container-closure conditions. Alkaline dilution systems should be avoided unless compatibility is specifically established.

Can dacarbazine be formulated as a premixed infusion?

Yes, but the liquid product must establish chemical stability, particulate control, container compatibility, sterility assurance and acceptable storage conditions. These requirements make a premixed infusion more difficult than the conventional lyophilized vial.

Does dacarbazine have biosimilar competition?

No. Dacarbazine is a chemically synthesized small molecule. Competing products are regulated as generic drugs, not biosimilars.

Is a new dacarbazine formulation eligible for patent protection?

Potentially. Protection is most credible for a formulation with demonstrated unexpected stability, improved reconstitution, reduced light sensitivity, improved container compatibility or meaningful workflow performance.

What is the most attractive commercial presentation for dacarbazine?

A ready-to-dilute concentrate or ready-to-use infusion bag is the most attractive differentiated presentation. A standard powder vial remains easier to develop but is more exposed to price competition.

References

1. National Cancer Institute. (n.d.). Dacarbazine. National Cancer Institute Drug Dictionary. https://www.cancer.gov

2. U.S. Food and Drug Administration. (n.d.-a). Dacarbazine for injection prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Pharmacopeia. (2023). General chapter <797>: Pharmaceutical compounding, sterile preparations. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (n.d.-c). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/